You are here

Approvals, Launches, and New Indications

Statistically Significant Improvement in Excessive Daytime Sleepiness
100% of Responders Maintained Response for 12 Months or More
Showed Significant Improvement in Metastasis-Free Survival
May Be Used in Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Polyangiitis
Otezla Approved for Behçet’s Syndrome
For Diabetic Neuropathic Pain, Fibromyalgia, Partial-Onset Seizures, and More
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Patient Access to Inhaler Use Data Could Improve Asthma Management
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Dupilumab Also Reduces Need for Polyp Surgery and Steroids
Patients Had Improved Lung Function, Fewer Exacerbations
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Over Half of Patients Had Reduced Pain Levels of 30% or More
Over 25% of Study Patients Showed 6–12 Months Remission
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
Nexus Has Increased Power, RF Capabilities
New Indication for Ceftolozane/Tazobactam Injection
FDA Approves Combination Treatment for Relapsed/Refractory NHL
Only FDA-Approved Therapy for GVHD in Adults and Children
Rare SMA is Leading Genetic Cause of Infant Mortality
Data Show Drug Significantly Prolongs Survival
First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
First New Medication for Seizure Clusters in More Than Two Decades